Close Menu

North America

Early sub-protocol results presented at AACR meeting hint at better outcomes for Mektovi-treated cases with NRAS codon 61 tumor mutations.

Investigators from the Friends of Cancer Research's tumor mutational burden harmonization project shared new data this week at AACR's virtual meeting.

The analysis presented at the AACR Virtual Annual Meeting confirmed the effectiveness of the TRK inhibitor to treat cancer patients with NTRK gene fusions.

Researchers also found that a subgroup of patients who had been hormone receptor-positive and converted to TNBC status responded especially well to the therapy.

WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.

Additional analyses found the talazoparib arm reported a better quality of life and a limited effect of broader tumor genomic markers on clinical benefit or progression-free survival.

At the AACR annual meeting, researchers shared detection rate data for multi-cancer screening tests from Grail and Thrive Earlier Detection.

RemeGen's anti-HER2 antibody drug conjugate disitamab vedotin already achieved an overall response rate of 60 percent in a Phase II trial conducted in China.

Research reported at the AACR annual meeting suggests mutations in the estrogen receptor gene ESR1 in untreated primary breast cancers can influence endocrine treatment response.

The project is collaborating with nine biopharma companies to combine more real-world clinical data with genomic data.